Synchronous hepatocellular carcinoma and Castleman's disease: The role of the interleukin‐6‐signaling pathway

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-3350|56|1|392-393

ISSN： 0270-9139

Source： HEPATOLOGY, Vol.56, Iss.1, 2012-07, pp. : 392-393

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Interleukin-6 Polymorphisms and Gender: Relationship with the Occurrence of Hepatocellular Carcinoma in Patients with End-Stage Liver Disease

By  

Oncology, Vol. 77, Iss. 5, 2009-11 ,pp. : 304-313

Karger

Access to resources Recommend Favorite

Successful Treatment of Autoimmune Hemolytic Anemia Associated with Multicentric Castleman Disease by Anti-Interleukin-6 Receptor Antibody (Tocilizumab) Therapy

By  

Acta Haematologica, Vol. 126, Iss. 3, 2011-07 ,pp. : 147-150

Karger

Access to resources Recommend Favorite

Signaling Pathways in Hepatocellular Carcinoma

By  

Oncology, Vol. 81, Iss. 1, 2011-12 ,pp. : 18-23

Karger

Access to resources Recommend Favorite

Role of the MAPKs/TGF-β1/TRAF6 Signaling Pathway in Atrial Fibrosis of Patients with Chronic Atrial Fibrillation and Rheumatic Mitral Valve Disease

By  

Cardiology, Vol. 129, Iss. 4, 2014-11 ,pp. : 216-223

Karger

Access to resources Recommend Favorite

Contribution of the Interleukin‐6/STAT‐3 Signaling Pathway to Chondrogenic Differentiation of Human Mesenchymal Stem Cells

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 5, 2015-05 ,pp. : 1250-1260

John Wiley & Sons Inc

Access to resources Recommend Favorite